

Marie Christine BÃ©nÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5539622/publications.pdf>

Version: 2024-02-01

153
papers

5,199
citations

147801
31
h-index

95266
68
g-index

156
all docs

156
docs citations

156
times ranked

6100
citing authors

#	ARTICLE	IF	CITATIONS
1	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2018, 131, 1275-1291.	1.4	796
2	Clinical and biologic features of CD4+CD56+ malignancies. <i>Blood</i> , 2002, 99, 1556-1563.	1.4	404
3	Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 1250-1260.	27.0	313
4	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. <i>Blood</i> , 2021, 138, 2753-2767.	1.4	305
5	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 3739-3749.	1.4	281
6	Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. <i>Blood</i> , 2011, 117, 3163-3171.	1.4	252
7	Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. <i>British Journal of Haematology</i> , 2009, 145, 624-636.	2.5	163
8	Validation of cellâ€based fluorescence assays: Practice guidelines from the ICSH and ICCS â€“ part V â€“ assay performance criteria. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84, 315-323.	1.5	153
9	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	1.8	153
10	R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 174-181.	1.4	121
11	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1378-1390.	10.7	84
12	Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group. <i>Haematologica</i> , 2017, 102, 308-319.	3.5	74
13	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019, 3, 4238-4251.	5.2	72
14	Acute leukemias of ambiguous lineage. <i>Seminars in Diagnostic Pathology</i> , 2012, 29, 12-18.	1.5	68
15	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. <i>Leukemia and Lymphoma</i> , 2013, 54, 472-475.	1.3	66
16	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2017, 130, 1832-1844.	1.4	66
17	Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia. <i>Acta Haematologica</i> , 2019, 141, 232-244.	1.4	57
18	Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2021, 4, e2126344.	5.9	55

#	ARTICLE	IF	CITATIONS
19	Bendamustine plus rituximab in newly diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). <i>British Journal of Haematology</i> , 2019, 186, 146-149.	2.5	51
20	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. <i>Haematologica</i> , 2018, 103, 1593-1603.	3.5	49
21	Acute Leukemias of Ambiguous Origin. <i>American Journal of Clinical Pathology</i> , 2015, 144, 361-376.	0.7	46
22	Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. <i>Oncotarget</i> , 2018, 9, 11451-11464.	1.8	46
23	Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. <i>Blood</i> , 2012, 119, 2943-2948.	1.4	45
24	Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias!. <i>Haematologica</i> , 2009, 94, 891-893.	3.5	44
25	Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group. <i>Haematologica</i> , 2014, 99, 46-53.	3.5	44
26	Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. <i>Haematologica</i> , 2018, 103, e143-e146.	3.5	41
27	Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia. <i>British Journal of Haematology</i> , 2013, 161, 551-555.	2.5	38
28	Humoral response to mRNA anti-“COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 207-211.	5.2	38
29	Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: A reference document based on a systematic approach by the GTLLF and GEIL. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 4-10.	1.5	36
30	Addition of Lomustine to Idarubicin and Cytarabine Improves the Outcome of Elderly Patients With De Novo Acute Myeloid Leukemia: A Report From the GOELAMS. <i>Journal of Clinical Oncology</i> , 2010, 28, 3028-3034.	1.6	36
31	Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL study. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2013, 83, 1066-1072.	1.5	36
32	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. <i>HemaSphere</i> , 2022, 6, e676.	2.7	35
33	Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 183-194.	1.5	33
34	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3203-3210.	1.6	32
35	Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide. <i>Journal of Immunology</i> , 2019, 202, 2141-2152.	0.8	32
36	Disruption of gap junctions attenuates acute myeloid leukemia chemoresistance induced by bone marrow mesenchymal stromal cells. <i>Oncogene</i> , 2020, 39, 1198-1212.	5.9	32

#	ARTICLE	IF	CITATIONS
37	An Râ€Derived FlowSOM Process to Analyze Unsupervised Clustering of Normal and Malignant Human Bone Marrow Classical Flow Cytometry Data. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 1191-1197.	1.5	28
38	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. Haematologica, 2015, 100, e128-e131.	3.5	26
39	Safety and antibody response after one and/or two doses of BNT162b2 Antiâ€SARSâ€CoVâ€2 mRNA vaccine in patients treated by CAR T cells therapy. British Journal of Haematology, 2022, 196, 360-362.	2.5	24
40	SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine. Vaccines, 2022, 10, 448.	4.4	24
41	Good IgA Bad IgG in SARS-CoV-2 Infection?. Clinical Infectious Diseases, 2020, 71, 897-898.	5.8	23
42	Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia. Cancers, 2021, 13, 629.	3.7	23
43	Leukemia diagnosis: today and tomorrow. European Journal of Haematology, 2015, 95, 365-373.	2.2	21
44	Innovation in Flow Cytometry Analysis: A New Paradigm Delineating Normal or Diseased Bone Marrow Subsets Through Machine Learning. HemaSphere, 2019, 3, e173.	2.7	21
45	Interest of a third dose of BNT162b2 antiâ€SARSâ€CoVâ€2 messenger RNA vaccine after allotransplant. British Journal of Haematology, 2022, 196, .	2.5	21
46	Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Advances, 2019, 3, 4271-4279.	5.2	19
47	Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations. Haematologica, 2018, 103, e13-e16.	3.5	18
48	Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematological Oncology, 2018, 36, 422-428.	1.7	18
49	CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM. Blood, 2021, 138, 243-243.	1.4	18
50	Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDSâ€Flow</scp> Cytometry Working Group. Cytometry Part B - Clinical Cytometry, 2023, 104, 77-86.	1.5	18
51	Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. Oncotarget, 2018, 9, 33528-33535.	1.8	17
52	Detection of phosphatidyl serine on activated platelets' surface by flow cytometry in whole blood: a simpler test for the diagnosis of Scott syndrome. British Journal of Haematology, 2015, 171, 290-292.	2.5	16
53	<scp>CD</scp>180 expression in <scp>B</scp>-cell lymphomas: A multicenter <scp>GEIL</scp> study. Cytometry Part B - Clinical Cytometry, 2016, 90, 462-466.	1.5	16
54	Flow cytometric analysis of myelodysplasia: Preâ€analytical and technical issuesâ€Recommendations from the European <scp>LeukemiaNet</scp>. Cytometry Part B - Clinical Cytometry, 2023, 104, 15-26.	1.5	16

#	ARTICLE	IF	CITATIONS
55	The routine leukocyte differential flow cytometry <sc>H</sc>emato<sc>F</sc>lowâ„¢ method: A new flagging system for automatic validation. Cytometry Part B - Clinical Cytometry, 2015, 88, 375-384.	1.5	15
56	A new mutation of <i><sc>ANO</sc></i>6 in two familial cases of Scott syndrome. British Journal of Haematology, 2018, 180, 750-752.	2.5	15
57	A novel complete blood countâ€based score to screen for myelodysplastic syndrome in cytopenic patients. British Journal of Haematology, 2018, 183, 736-746.	2.5	15
58	Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?. Hematological Oncology, 2019, 37, 80-84.	1.7	15
59	Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia. Cancers, 2020, 12, 1927.	3.7	15
60	Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. Blood, 2012, 119, 2474-2477.	1.4	14
61	In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study. Blood Advances, 2022, 6, 1804-1812.	5.2	14
62	Unsupervised flow cytometry analysis in hematological malignancies: A new paradigm. International Journal of Laboratory Hematology, 2021, 43, 54-64.	1.3	13
63	Platelet immunophenotyping in health and inherited bleeding disorders, a review and practical hints. Cytometry Part B - Clinical Cytometry, 2020, 98, 464-475.	1.5	12
64	Centromeric KIR AA Individuals Harbor Particular KIR Alleles Conferring Beneficial NK Cell Features with Implications in Haplo-Identical Hematopoietic Stem Cell Transplantation. Cancers, 2020, 12, 3595.	3.7	11
65	Flow cytometry in the diagnosis of mature Bâ€cell lymphoproliferative disorders. International Journal of Laboratory Hematology, 2020, 42, 113-120.	1.3	11
66	Automated Early Detection of Myelodysplastic Syndrome within the General Population Using the Research Parameters of Beckmanâ€Coulter DxH 800 Hematology Analyzer. Cancers, 2021, 13, 389.	3.7	11
67	Occupational pesticide exposure increases risk of acute myeloid leukemia: a meta-analysis of caseâ€control studies including 3,955 cases and 9,948 controls. Scientific Reports, 2021, 11, 2007.	3.3	11
68	Panel proposal for the immunophenotypic diagnosis of hematological malignancies. A collaborative consensus from the groupe d'Etude Immunologique des LeucĂ©mies (GEIL). Cytometry Part B - Clinical Cytometry, 2018, 94, 542-547.	1.5	10
69	Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia. Leukemia, 2019, 33, 1814-1816.	7.2	10
70	CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. British Journal of Haematology, 2019, 184, 625-633.	2.5	10
71	B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 279.e1-279.e4.	1.2	10
72	Bleeding risk for patients with haemophilia under antithrombotic therapy. Results of the French multicentric study <sc>ERHEA</sc>. British Journal of Haematology, 2019, 185, 764-767.	2.5	9

#	ARTICLE	IF	CITATIONS
73	Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution. <i>Journal of Immunology</i> , 2020, 205, 1441-1448.	0.8	9
74	Involvement of GPx-3 in the Reciprocal Control of Redox Metabolism in the Leukemic Niche. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8584.	4.1	8
75	Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. <i>Blood Advances</i> , 2020, 4, 5322-5335.	5.2	8
76	Mixed Phenotype/Lineage Leukemia: Has Anything Changed for 2021 on Diagnosis, Classification, and Treatment?. <i>Current Oncology Reports</i> , 2022, 24, 1015-1022.	4.0	8
77	Effectiveness of a third dose of BNT162b2 antiâ€SARSâ€CoVâ€2 mRNA vaccine over a 6â€month followâ€up period in allogeneic hematopoietic stem cells recipients. <i>Hematological Oncology</i> , 2022, 40, 1097-1099.	1.7	8
78	The closely related rare and severe acute myeloid leukemias carrying EVI1 or PRDM16 rearrangements share singular biological features. <i>Haematologica</i> , 2015, 100, e114-e115.	3.5	7
79	<scp>CD200</scp> expression in flow cytometry helps to distinguish mantle cell lymphoma from other <scp>CD</scp>5â€positive <scp>B</scp>â€cell neoplasms. <i>Hematological Oncology</i> , 2018, 36, 607-609.	1.7	7
80	Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. <i>Annals of Hematology</i> , 2020, 99, 1341-1350.	1.8	7
81	Definition of Erythroid Differentiation Subsets in Normal Human Bone Marrow Using FlowSOM Unsupervised Cluster Analysis of Flow Cytometry Data. <i>HemaSphere</i> , 2021, 5, e512.	2.7	7
82	Impact of bodyâ€surface area on patientsâ€â€™ outcome in younger adults with acute myeloid leukemia. <i>European Journal of Haematology</i> , 2017, 98, 443-449.	2.2	6
83	Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018, 53, 1044-1047.	2.4	6
84	Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood Bâ€Lineage Lymphoblastic Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 128-133.	1.5	6
85	Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 906-911.	2.0	6
86	Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 995-1003.	2.1	6
87	Low-Dose Pesticides Alter Primary Human Bone Marrow Mesenchymal Stem/Stromal Cells through ALDH2 Inhibition. <i>Cancers</i> , 2021, 13, 5699.	3.7	6
88	Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and <scp>JAK</scp> inhibitors era?. <i>European Journal of Haematology</i> , 2017, 99, 60-69.	2.2	5
89	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the <scp>LYSA</scp> group. <i>Hematological Oncology</i> , 2020, 38, 446-455.	1.7	5
90	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , 2021, 35, 1291-1300.	7.2	5

#	ARTICLE	IF	CITATIONS
91	Platelet features allow to differentiate immune thrombocytopenia from inherited thrombocytopenia. <i>Annals of Hematology</i> , 2021, 100, 2677-2682.	1.8	5
92	CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy. <i>Blood</i> , 2016, 128, 5268-5268.	1.4	5
93	Unsupervised cluster analysis and subset characterization of abnormal erythropoiesis using the bioinformatic <sc>Flowâ€self</sc> Organizing Maps algorithm. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 134-142.	1.5	5
94	A series of case studies illustrating the role of flow cytometry in the diagnostic workâ€up of myelodysplastic syndromes. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, , .	1.5	5
95	Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report. <i>Acta Haematologica</i> , 2022, 145, 537-541.	1.4	5
96	Major impact of an early bone marrow checkpoint (day 21) for minimal residual disease in flow cytometry in childhood acute lymphoblastic leukemia. <i>Hematological Oncology</i> , 2017, 35, 237-243.	1.7	4
97	A new case of heterozygous variant of the <i><sc>GP</sc>1<sc>BB</sc></i> gene responsible for macrothrombocytopenia. <i>British Journal of Haematology</i> , 2019, 186, 157-159.	2.5	4
98	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. <i>Acta OncolÃ³gica</i> , 2021, 60, 466-474.	1.8	4
99	Molecular Signature of ¹⁸F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1008-1013.	5.0	4
100	Antiâ€SARSâ€CoVâ€2 vaccines in recipient and/or donor before allotransplant. <i>EJHaem</i> , 2022, , .	1.0	4
101	Evaluation of minimal residual disease in childhood <sc>ALL</sc>. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 104-108.	1.3	3
102	Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. <i>Scientific Reports</i> , 2020, 10, 15399.	3.3	3
103	Reactive oxygen species levels differentiate CD34 + human progenitors based on CD38 expression. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 516-521.	1.5	3
104	Effect of DDAVP on Platelet Activation and Platelet-Derived Microparticle Generation. <i>Hamostaseologie</i> , 2022, 42, 185-192.	1.9	3
105	Research in morphology and flow cytometry is at the heart of hematology. <i>Haematologica</i> , 2017, 102, 421-422.	3.5	2
106	The wonderful story of monoclonal antibodies. <i>International Journal of Laboratory Hematology</i> , 2019, 41, 8-14.	1.3	2
107	RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation. <i>EJHaem</i> , 2020, 1, 318-322.	1.0	2
108	Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status. <i>European Journal of Haematology</i> , 2021, 106, 859-867.	2.2	2

#	ARTICLE	IF	CITATIONS
109	Post-SARS-CoV-2 vaccination specific antibody decrease : Let's get the half-full glass perspective. Journal of Infection, 2022, 84, 94-118.	3.3	2
110	The Plasmacytoid Dendritic Cell CD123+ Compartment in Acute Leukemia with or without RUNX1 Mutation: High Inter-Patient Variability Disclosed by Immunophenotypic Unsupervised Analysis and Clustering. Hemato, 2021, 2, 572-585.	0.6	2
111	Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma. Blood, 2019, 134, 1799-1799.	1.4	2
112	Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies. Bone Marrow Transplantation, 2022, 57, 1435-1441.	2.4	2
113	Innovation in hematology: morphology and flow cytometry at the crossroads. Haematologica, 2016, 101, 394-395.	3.5	1
114	Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII?. Transfusion Medicine Reviews, 2020, 34, 128-129.	2.0	1
115	Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma. Annals of Hematology, 2021, 100, 285-287.	1.8	1
116	Therapeutic targets in childhood B-acute lymphoblastic leukemia: what about HER2/neu?. Hematological Oncology, 2021, 39, 270-272.	1.7	1
117	Large-Scale Proteomics Identifies Distinct Signatures for Richter Syndrome and De Novo Diffuse Large B-Cell Lymphoma: A French Study from the Filo Group. Blood, 2020, 136, 29-30.	1.4	1
118	Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial. Blood, 2015, 126, 3787-3787.	1.4	1
119	First Line Chronic Lymphocytic Leukemia Immunochemotherapy for the Elderly Patients over 79 Years Is Feasible, and Achieves Good Results: A Filo Retrospective Study. Blood, 2015, 126, 4170-4170.	1.4	1
120	Comparative Value of the Assessment of Minimal Residual Disease in Peripheral Blood at Days 8 and 15 By Flow Cytometry in Childhood Acute Lymphoblastic Leukemia. Blood, 2016, 128, 5270-5270.	1.4	1
121	Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 3911-3911.	1.4	1
122	Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy. Blood, 2021, 138, 254-254.	1.4	1
123	A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Gvhd Prophylaxis after Matched Allotransplant Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft. Blood, 2021, 138, 1812-1812.	1.4	1
124	Morphology and immunophenotyping issues in the integrated diagnosis of hematologic disorders of elderly patients. Haematologica, 2014, 99, 951-953.	3.5	0
125	Place de la cytométrie en flux dans le diagnostic et le suivi des leucémies aiguës. Revue Francophone Des Laboratoires, 2015, 2015, 35-41.	0.0	0
126	Flow cytometry for platelets, EDTA or not EDTA: what is the answer?. Platelets, 2021, 32, 144-145.	2.3	0

#	ARTICLE	IF	CITATIONS
127	Fortuitous discovery of an NPM1 mutation in a myelodysplastic syndrome. International Journal of Laboratory Hematology, 2021, 43, 1258-1259.	1.3	0
128	Letter to the editor with regard to the article entitled "Automated leukocyte parameters are useful in the assessment of myelodysplastic syndromes" Cytometry Part B - Clinical Cytometry, 2022, 102, 76-76.	1.5	0
129	Interference in platelet count due to microspherocytosis related to extensive burn injury. International Journal of Laboratory Hematology, 2022, 44, 57-58.	1.3	0
130	Issue Highlights"September 2021. Cytometry Part B - Clinical Cytometry, 2021, 100, 537-540.	1.5	0
131	Hemophagocytic lymphohistiocytosis, what about hair?. American Journal of Hematology, 2022, 97, 508-509.	4.1	0
132	Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation. Blood, 2015, 126, 3218-3218.	1.4	0
133	Post-Transplant Cyclophosphamide (PTCY) Versus Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes. Blood, 2015, 126, 4339-4339.	1.4	0
134	Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome. Blood, 2015, 126, 1947-1947.	1.4	0
135	Engraftment of Donor Cells after Allogeneic Stem Cell Transplantation: Comparison and Impact of Chimerism in Whole Blood and Peripheral CD3+ T-Cells. Blood, 2016, 128, 5866-5866.	1.4	0
136	Cytométrie en flux. , 2018, , 27-39.		0
137	Maladie résiduelle moléculaire. , 2018, , 301-306.		0
138	Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy " a Study By the Lysa Group. Blood, 2018, 132, 4099-4099.	1.4	0
139	Correlations between p16 Protein Expression and Genomic Profile in Mantle Cell Lymphoma and Impact on Survival, a Lyma-Genomic Project Conducted on Behalf of the Lysa Group. Blood, 2018, 132, 2846-2846.	1.4	0
140	Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group. Blood, 2019, 134, 4112-4112.	1.4	0
141	Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation. Blood, 2019, 134, 3319-3319.	1.4	0
142	Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allogeneic Transplant Using Purine Analogue/Busulfan-Based Conditioning Regimen. Blood, 2019, 134, 1985-1985.	1.4	0
143	Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies. Blood, 2019, 134, 5771-5771.	1.4	0
144	Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients. Blood, 2021, 138, 3908-3908.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy. Blood, 2021, 138, 3465-3465.	1.4	0
146	Comparable Outcomes Among Adult Patients Allografted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study. Blood, 2021, 138, 4914-4914.	1.4	0
147	Single Capture High Throughput Sequencing Assay for Combined V(D)J Clonality Analysis and Oncogene Mutations in the Diagnosis of T and B Lymphoid Malignancies. Blood, 2021, 138, 2404-2404.	1.4	0
148	Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine. Blood, 2021, 138, 2895-2895.	1.4	0
149	Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases. Blood, 2020, 136, 2-3.	1.4	0
150	Unsupervised Flow Cytometry Analysis: Application to Minimal Residual Disease Detection in a Cohort of 40 Acute Myeloblastic Leukemia Patients with Molecular Markers. Blood, 2020, 136, 30-30.	1.4	0
151	Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis: A Retrospective Study of 223 Cases. Blood, 2020, 136, 37-38.	1.4	0
152	Suffering neutrophils – where is the enemy?. International Journal of Laboratory Hematology, 2022, 44, 806-807.	1.3	0
153	Lineage switch and relapse in sanctuary site: Some lessons to learn about plasticity in <i>KMT2Ar</i> acute leukemia. Pediatric Blood and Cancer, 2022, 69, e29683.	1.5	0